One opioid drugmaker's solution to billions of potential liabilities: spin them out into new company
July 23, 2019 at 06:00 AM EDT
Mallinckrodt Pharmaceuticals plans to separate its business into two: one with its brand-name medicines; the other with its specialty generic drugs — including ooxycodone and hydrocodone.
